Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 3Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 4Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Radiation Pneumonitis 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Neoplasms by Site 1Lung Diseases 1Locally Advanced Gastric Cancer 1Esophageal Malignant Neoplasm, Local Recurrence 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced NSCLC 1Advanced Esophageal Cancer 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × camrelizumab × Clear all
NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
80 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡